BlossomHill Therapeutics, Inc. (BLSM)
NASDAQ · Manufacturing · Pharmaceutical preparations
BLSM price, last 12 months
Key stats
- Previous close
- $14.41
- Open
- $14.34
- Day range
- $13.90 – $15.63
- 52-week range
- $11.02 – $27.99
- Volume
- 270.7K
- Avg volume (20 days)
- 202.8K
- Market cap
- $445.6M
Performance
Technicals and fundamentals
About BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $445.6M